Clinical Trial Update: Safety, Tolerability & Immunogenicity of the Recombinant Plague Vaccine rF1V [Phase 1]

View source ↗

Summary

A Phase 1 trial evaluated the safety, tolerability, and immunogenicity of the recombinant plague vaccine rF1V for pneumonic plague preventive therapy; the study…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pneumonic Plague

Drugs mentioned

• rF1V recombinant plague vaccine (rF1V)

Snippet

Sponsor: DynPort Vaccine Company LLC, A GDIT Company | Conditions: Pneumonic Plague, Preventive Therapy | Phase 1 | Status: COMPLETED